Home
Interesting shortcuts
EFFRA Members' Perspectives
News Dashboard
Projects
Projects
Results, demos etc.
Results, demos etc.
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
Company perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards and standardisation
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
Public Consultation - MiE 25-27 Priorities (input is publicly available)
MiE KPIs
Relevant open calls
EU-Programme-Call
NACE code
EFFRA WG pointers
Pathways
Pathways
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
IMI2-2018-16-01 Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Associated lists
In list:
EU-Programme-Call
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-16-single-stage
IMI2-2018-16-01 Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors